Publications
Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.
Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Transthyretin Amyloidosis (ATTR)
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
American Journal of Transplantation
Primary Hyperoxaluria Type 1 (PH1)
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Kidney International Reports
Primary Hyperoxaluria Type 1 (PH1)
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
Genetics in Medicine
Primary Hyperoxaluria Type 1 (PH1)
Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study
Frontiers in Medicine
Acute Hepatic Porphyria (AHP)
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver
Clinical Pharmacology and Therapeutics
Transthyretin Amyloidosis (ATTR)
Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program
Circulation: Genomic and Precision Medicine
Primary Hyperoxaluria Type 1 (PH1)
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial
Clinical Journal of the American Society of Nephrology
Primary Hyperoxaluria Type 1 (PH1)
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine
Cardiovascular (CV)
Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease
Hypertension
Cardiovascular (CV)
No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension
Clinical Science
